Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study

Varování

Publikace nespadá pod Filozofickou fakultu, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	ROOS Izanne SHARMIN Sifat HORAKOVA Dana KUBALA HAVRDOVA Eva LIBERTINOVA Jana VACHOVA Marta ALROUGHANI Raed BOZ Cavit ROUS Zuzana BUZZARD Katherine SKIBINA Olga PETERKA Marek HRADILEK Pavel MARES Miroslav COLES Alasdair BROWN J William L SARA Eichau Madueno FOSCHI Matteo PREVOST Julie TERZI Murat PRAT Alexandre GIRARD Marc MECA-LALLANA Jose E JOHN Nevin BLANCO Yolanda ANNEKE van der Walt BUTZKUEVEN Helmut RECMANOVA Eva LAUREYS Guy AMPAPA Radek MACDONELL Richard PAVELEK Zbysek KHOURY Samia Joseph D'AMICO Emanuele GERLACH Oliver VINCENT Van Pesch MAIMONE Davide ROMERO-FERRANDO Beatriz MCCOMBE Pamela A MRABET Saloua WILLEKENS Barbara CARDENAS-ROBLEDO Simon RAMO-TELLO Cristina ŠTOURAČ Pavel HOUSKOVA Jana SHAYGANNEJAD Vahid HODGKINSON Suzanne CARTECHINI Elisabetta KERMODE Allan G FABIS-PEDRINI Marzena CARROLL William M SLEE Mark SANCHEZ-MENOYO Jose Luis AL-ASMI Abdullah MATHEY Guillaume GIANNESINI Claire MICHEL Laure CIRON Jonathan JEROME De Seze RUET Aurelie KWIATKOWSKI Arnaud ZEPHIR Helene PAPEIX Caroline LEBRUN-FRENAY Christine MOREAU Thibault BERGER Eric CLAVELOU Pierre PELLETIER Jean CASEZ Olivier BOURRE Bertrand WAHAB Abir MAGY Laurent CAMDESSANCHE Jean-Philippe DOGHRI Ines TCHIKVILADZE Maia SELLEBJERG Finn JEPPE Romme Christensen JENSEN Henrik Boye ILLES Zsolt BRAMOW Stephan RASMUSSEN Peter V STILUND Morten Leif SCHAFER Jakob KANT Matthias WEGLEWSKI Arkadiusz VUKUSIC Sandra MAGYARI Melinda LAPLAUD David-Axel KALINCIK Tomas
Rok publikování	2026
Druh	Recenzovaný odborný článek
Časopis / Zdroj	Journal of Neurology, Neurosurgery, and Psychiatry
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://jnnp.bmj.com/content/early/2026/05/20/jnnp-2026-338424
Doi	https://doi.org/10.1136/jnnp-2026-338424
Klíčová slova	MULTIPLE SCLEROSIS
Popis	Background Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, is a high-efficacy therapy for multiple sclerosis (MS). Methods Patients with relapse-onset MS treated with ocrelizumab, fingolimod, natalizumab or alemtuzumab for >= 6 months were identified from three registries: MSBase, OFSEP and Danish MS Registry. Pairwise comparisons were performed in the overall cohort and 14 predefined clinicodemographic subgroups based on sex, disease activity, MS duration, Expanded Disability Status Scale, prior therapy and reason for prior treatment cessation. Relapses, progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) were compared in pairwise-censored groups. Results Fingolimod was associated with a higher annualised relapse rate (ARR) (0.14 vs 0.06, p<0.001), relapse risk (HR 2.26, 95% CI 1.98 to 2.58), RAW (1.62, 1.08 to 2.43) and lower risk of disability improvement (0.78, 0.63 to 0.96) than ocrelizumab. Superiority of ocrelizumab over fingolimod on relapses was maintained in all subgroups. Natalizumab was associated with marginally higher ARR (0.10 vs 0.07, p<0.001), relapse risk (1.35, 1.16 to 1.57) and RAW (1.77, 1.07 to 2.94) than ocrelizumab. Alemtuzumab was associated with higher ARR (0.18 vs 0.12, p<0.001) and relapse risk (1.48, 1.25 to 1.76) than ocrelizumab, but there was no evidence for a difference in risk of RAW. There was no evidence for a difference on PIRA in any comparisons. Ocrelizumab was superior to natalizumab and alemtuzumab on relapses in patients who were not treatment-naive, experienced disease activity on the prior therapy or stopped prior therapy due to lack of efficacy. Conclusions Ocrelizumab provides superior control of relapses and RAW, especially among patients with prior on-treatment disease activity. Treatment of PIRA remains an unmet need.
Související projekty:	Národní ústav pro neurologický výzkum